VEGFA and gastrointestinal stromal tumor: Based on these data, illustrating that the FGF/FGFR pathway might be implicated in GIST resistance to IM and taking into account that multi-kinase inhibitors used as the second and third therapies for IM-refractory GISTs potently inhibit VEGF/VEGFR signaling, we thought to examine the potential cross-talk between FGF/FGFR and VEGF/VEGFR pathways in IM-resistant GISTs and further evaluate their anti-proliferative and cytotoxic activities when used in combination with BGJ 398, a well-known pan-FGFR inhibitor.